With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE:ATNM) with an Overweight rating and a price target of $20, almost an upside…
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Exelixis Inc (NASDAQ:EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced…
Gilead’s Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
Gilead Sciences Inc (NASDAQ:GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus…
Erasca Touts Promising Early Data From Lead Cancer Programs
Erasca Inc (NASDAQ:ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings. A retrospective pooled analysis…
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
After Initial Skepticism FDA’s Adcomm Backs Amylyx’s Amyotrophic Lateral Sclerosis Hopeful
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted (7 yes and 2 no) that the…
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary…
NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders
Selexis SA and NexImmune Inc (NASDAQ:NEXI) have agreed to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs…
Mirati’s Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer
Mirati Therapeutics Inc (NASDAQ:MRTX) announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with…
Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate
The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in